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Abstract 
 
Pancreatic cancer is an aggressive cancer of the pancreas that has been shown to have 
extremely low survival rates.  It can be quite lethal because of its asymptomatic early stages and 
inability to detect cancer at the cellular level.  Once diagnosed, the cancer will have usually 
spread or metastasized beyond surgical resection.  Thus, research is focused on finding potential 
biomarkers in tumor cell lines to help in earlier diagnosis of this disease leading to better 
treatment options. Previous work using bioinformatics data suggest several cellular genes 
including, CTHCR1, EPPK1, AHNAK2, and IGHG3, can be potential biomarkers for pancreatic 
cancer. The goal of this project was to determine if protein expression of these genes was altered 
in a variety of human pancreatic tumor cell lines. Protein isolation and quantification followed 
by Western blot analysis was used. Our results showed a statistically significant increase of 
CTHCR1 protein expression in SW 1990, a pancreatic tumor cell line, compared to the HPDE-6 
control cell line. This data adds to the current evidence that CTHCR1 can act as a prospective 
pancreatic cancer biomarker. There was also increased CTHCR1 protein expression in four other 
human pancreatic tumorigenic cell lines, but they were not found statistically significant. EPPK1 
was another potential biomarker studied; however, its large molecular weight was a challenge 
and caused insufficient transfer of proteins. No bands were visualized. 
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Introduction 
 
The diagnosis of cancer is a life changing event. There are always many concerns and 
questions such as: has it spread, what is the prognosis, what are possible therapies, and how long 
is the life expectancy? Unfortunately, these questions usually have poor responses with regard to 
pancreatic cancer. Pancreatic cancer is an aggressive cancer called a “silent killer.” It typically 
has no symptoms in the early stages when surgical resection would be a preferred option. 
Currently, diagnostic detection strategies are not specific or universal for all patients.  By the 
time of diagnosis, the cancer has usually metastasized beyond surgery, and other treatment 
options still have low survival rates. Research suggests that there is significant need to discover 
new specific pancreatic cancer biomarkers which are a measurable substance in an organism 
whose presence is indicative of a certain disease or infection. New biomarkers specific to 
pancreatic cancer would help in earlier diagnosis. Based on previous work by Goonesekere et al. 
(2014), four genes, CTHCR1, EPPK1, AHNAK2, and IGHG3, have been suggested as potential 
biomarkers for pancreatic cancer. The purpose of my thesis project is to attempt to determine if 
these proteins can act as potential biomarkers.  The project seeks to determine if the level of 
protein expression of the four proteins is altered in several known human pancreatic tumor cell 
lines and verify their status as novel biomarkers in pancreatic cancer. After determining protein 
expression, we will be able to evaluate and better understand these genes as potential biomarkers 
for pancreatic cancer. This thesis work will add to the current literature about pancreatic cancer 
and potentially help in earlier diagnosis of this deadly disease leading to better prognosis, targets 
for therapeutic intervention, and treatment options.  
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Review of Literature 
Pancreatic Cancer 
The pancreas is a large organ deep in the abdomen with 2 glands: exocrine glands that 
secrete digestive enzymes into the duodenum and endocrine cells that release hormones into the 
blood stream. Exocrine glands and the duct where the enzymes are released make up more than 
95% of the pancreas while endocrine cells make up less than 4% (American Cancer Society, 
2015). The endocrine hormones produced, such as insulin and glucagon, are important in 
controlling blood sugar levels.  As reviewed in Singh et al. (2015), the majority of pancreatic 
tumors come from exocrine cells. Cancer cells can be described as growing out of control and 
invading other tissues due to their damaged DNA (American Cancer Society, 2015). The tumor 
cells can grow around a population of cancer stem cells; these are cells that have the ability to 
differentiate and self-renew. Even though not all tumors are cancerous, the exocrine and 
endocrine cells of the pancreas have different types of tumors which have different treatment and 
prognosis. Pancreatic ductal adenocarcinoma (PDAC) makes up approximately 90% of 
pancreatic tumors which consequently starts in the ductal epithelium of the pancreas (Singh et 
al., 2015).  Other less common types of exocrine cells include adenosquamous carcinomas, 
squamous cell carcinomas, signet ring cell carcinomas, undifferentiated carcinomas, and 
undifferentiated carcinomas with giant cells (American Cancer Society, 2015). Solid 
pseudopapillary neoplasms and ampullary cancer are other less common types, but more 
commonly treatable. Endocrine tumors are rarer and are commonly known as neuroendocrine 
tumors or islet cell tumors (American Cancer Society, 2015). They also generally have better 
prognosis than exocrine tumors. Since pancreatic cancer is typically asymptomatic in early 
stages and due to the metastasis of the disease, chances for cure at the time of diagnosis becomes 
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very difficult (McKinney et al., 2011). Pancreatic cancer (PC) is one of the most aggressive types 
of cancer in the United States with a median survival rate of less than six months according to 
McKinney et al. (2011). It is the fourth most common cause of cancer death in North America 
(Ouyang et al., 2000). 
  Pancreatic cancer is associated with an extremely poor prognosis due to the advanced 
stage in which it is usually detected; many times the cancer has metastasized and is unable to be 
resected surgically (Park et al., 2013). The location of the pancreas deep in the abdomen behind 
the stomach eliminates the ability to palpate tumors, and almost acts as a hidden, sanctuary site. 
Pancreatic cancer also can seem to come by “surprise” due to little to no known association with 
family history or other diseases that increase the risk of PC (Chakraborty et al., 2011). Pancreatic 
cancer is hereditarily complex. Age, however, is positively correlated and a majority of 
pancreatic patients are over the age of sixty (Singh et al., 2015). Approximately 10% of PC 
patients are thought to have a familial susceptibility with only a minority of these patients having 
an inherited component and usually the responsible gene cannot be identified (Sclafani et al., 
2015). There are also risk factors such cigarette smoking and alcohol abuse that are associated 
with the development of this cancer (Sclafani et al., 2015). Pancreatic cancer continues to be a 
struggle for clinicians and scientists in diagnosis, and little progress has been made in the 
treatment of the disease. There is a need to find the best route of care for each specific patient.   
Diagnosis 
Diagnosis has been difficult as not much progress has been made in biomarker 
identification in pancreatic cancer. A biomarker is a measurable indicator of a specific biological 
state, the presence or stage of a disease (Rifai et al., 2006). A biomarker can be the presence of a 
specific gene or protein, and they can be used to screen for, diagnosis, or monitor the activity of 
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diseases clinically. Clinically, the ultimate goal would be using a blood test or other readily 
accessible biological fluids to test to see if a certain biomarker indicative of a disease is present. 
These tests would be much faster and less invasive for patients and could be done at any time, 
making a possibility of earlier diagnosis available. Biomarkers are also used in molecularly 
targeted therapy (Rifai et al., 2006). However, their discoveries and implementations are 
challenging and slow. Currently, there a few genes that are found mutated in pancreatic cancer. 
Mutations in inherited genes such as BRCA2, p16, and the genes responsible for hereditary non-
poly colorectal cancer can increase a patient’s chances of developing PC (American Cancer 
Society, 2015). Another non-invasive type of diagnosis is done through the detection of serum 
markers in blood. CA19-9 is currently used and the most common to help detect pancreatic 
cancer; however, this molecular biomarker has low specificity, is not expressed in high levels in 
pancreatic cancer, and is also not constantly expressed in all PC patients (McKinney et al., 
2011). Some pancreatic cancers do not secrete CA 19-9 even at the later stages (Haab et al., 
2015). A variety of other serum markers have been reported to be elevated in pancreatic cancer; 
however, they too have low sensitivity and specificity, and currently very few of these serum 
markers have shown encouraging results (Bünger et al., 2011). Thus, there is great need for 
identifying more specific markers that can detect pancreatic cancer while the disease is in its 
early stages and that are found more consistently in PC patients (McKinney et al., 2011). The 
heterogeneity of pancreatic cancer and range of mutations identified is likely to account for its 
poor response to treatments and aggressiveness (Sclafani et al., 2015). The discovery of 
biomarkers is needed to detect the full spectrum of pancreatic cancer cases (Haab et al., 2015). 
Better PC screening would give patients earlier and better treatment options; therefore improving 
survival ratings. 
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Treatments  
Treating pancreatic cancer is usually unsuccessful for the patient with only 10-15% of 
patients amenable to surgery (Park et al., 2013). Other than tumor resection, most patients often 
have to turn to more intensive treatments such as conventional radiation and chemotherapy, 
which also can have adverse effects. The resistance to cytotoxic drugs and resection surgery 
along with PC’s asymptomatic and metastatic nature make treatment extremely difficult leading 
to high annual death rates. These annual mortality rates are even comparable to breast cancer 
which is diagnosed at a rate 5 times greater than pancreatic cancer (Howlader et al., 2011). PC 
patients have an approximate 5-year survival rate of less than 5% (Lee et al., 2010).  In 
summary, pancreatic cancer is one that that needs better methods of detection and screening 
while the tumor is still at an early stage. Even though therapies have improved over the past ten 
years, overall survival rates are still significantly low and new strategies are necessary.  
Detection of potential new biomarkers 
As stated previously, CA-19 is the biomarker currently used in pancreatic cancer 
diagnosis and progression; however, its sensitivity to pancreatic cancer is not high (McKinney et 
al., 2011). Therefore, research into finding other genes and markers of pancreatic cancer has 
been a high priority. In a meta-analysis of microarray datasets by Goonesekere and colleagues in 
2014, research focused on finding genes that were significantly upregulated in pancreatic cancer. 
The study found four genes that were upregulated that were not previously associated or had a 
known role with a cancer, specifically pancreatic cancer; AHNAK2, collagen triple helix repeat 
containing-1 (CTHCR1), immunoglobulin heavy constant gamma-3 (IGHG3), and epiplakin 
(EPPK1) were the four proteins. This thesis project was designed and based on this work.   
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CTHCR1 
The work by Goonesekere et al. (2014) suggested collagen triple helix repeat containing-
1 or CTHCR1 as a significantly up-regulated gene. CTHCR1 is a secreted protein approximately 
30 kilo Daltons (kDa), and expressed at high levels during vascular remodeling and tissue repair 
(Beachy et al., 2004). In a study performed by Tang et al. (2006), expression of CTHCR1 was 
investigated in twenty solid cancer types through western blotting and CTHCR1 expression in 
cancer cDNA arrays. Human CTHCR1 was detected and identified by western blot analysis in 
melanoma cell lines, and not in normal melanocytes showing its potential as being expressed in 
cancer but not normal cells. In the other part of the study by Tang et al. (2006), they used a 
CTHCR1 specific gene probe to hybridize around 300 samples of cDNA from clinical tumor 
biopsies along with a matching benign tumor biopsy. Results showed that CTHCR1 gene levels 
were increased or upregulated (abnormally higher) in a majority of the cancers represented  such 
as cancers of the rectum, small intestine, colon, liver, lung, ovary, pancreas, and breast, 
compared to the normal, control tissues (Tang et al., 2006). This can give optimism and perhaps 
makes this gene an attractive option for developing a potentially new biomarker for various 
cancers.    
While CTHCR1 has been previously reported to be present in other carcinomas with poor 
survival rates such as melanoma, breast cancer, colorectal, and gastric cancer, CTHCR1 has only 
been associated with pancreatic cancer in a limited number of reports (reviewed in Goonesekere 
et al., 2014). CTHCR1 also seems to play a role in tumors that are aggressive in nature. Mice 
injected with CTHCR1 were found to have an increased number of tumor metastases. Results 
also showed CTHCR1 expression was strongly detected in pancreatic adenocarcinoma cells 
(Park et al., 2013) and that CTHCR1 expression enhances tumor progression, metastasis, tumor 
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cell migration, and adhesion. According to Tang et al. (2006), in metastatic melanoma, CTHCR1 
function is unclear, but results showed increased levels of tumor cell migration and tumor 
invasion by regulating the surrounding environment. There are indications that CTHCR1 may 
have a significant role in PC tumors, but it may not be required and all the functions are not 
completely understood (Park et al., 2013). Based on this work, the current project evaluated if 
increased CTHCR1 protein levels can serve as a potential biomarker for pancreatic cancer. 
EPPK1 
EPPK1, epiplakin, was another gene found to be significantly upregulated in the 
microarray meta- analysis of pancreatic cancer by Goonesekere et al. (2014). Epiplakin is an 
unusual protein compared to other members in the plakin family of cytolinker proteins that are 
associated with the cytoskeleton and junctional complexes. EPPK1 may participate in supporting 
intermediate filaments however specific function of this very large 552 kDa protein is not 
precisely known.  It has been found to be expressed in the pancreas and pancreatic ductal 
adenocarcinomas and may be a useful biomarker for pancreatic cancer (Yoshida et al., 2008).  
This increased expression in pancreatic tissue provides potential for this gene and protein 
product to be evaluated as a potential biomarker of pancreatic cancer.  
IGHG3 
Immunoglobulin heavy constant gamma-3 (IGHG3) was another potential PC biomarker 
cited by Goonesekere et al. (2014). This gene was significantly upregulated. It is known that 
IGHG3 is a secreted antigen binding protein, but has no assigned function at this time 
(Goonesekere et al., 2014).  IGHG3 has not been directly associated with specific cancer 
development or progression.  
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AHNAK2 
AHNAK2 is a large protein like EPPK1, with an estimated size of approximately 600 
kDa. AHNAK2 is the second protein in the AHNAK family along with AHNAK. AHNAK2 was 
found to be significantly upregulated gene in pancreatic cancer in the meta-analysis 
(Goonesekere et al., 2014). Numerous studies have contributed to finding the function of 
AHNAK2; however the specific function is unknown. The protein AHNAK has been associated 
with forming part of multi-protein complexes, most likely acting as a structural support, which 
AHNAK2 may share similarities with (Davis et al., 2014). AHNAK has been linked to several 
muscular diseases and may be functional component to the costameric network (Goonesekere et 
al., 2014).  
There are limited studies linking the role of AHNAK2 in cancer (Davis et al. 2014); 
however, there was discovery that AHNAK was significantly enriched in purified pseudopodia 
of six different metastatic cancer cell lines and another study showed that knockdown of 
AHNAK resulted in decreased migration and invasion of the cancer cells. In contrasting studies, 
AHNAK was described as a protein that functions as a repressor of cancer, that is, it acts as a 
tumor suppressor (Davis et al., 2014). While the exact function of AHNAK2 and AHNAK may 
be unclear, they seem to have a large diversity of roles possibly pertaining to cancer, especially 
pancreatic cancer. The meta-analysis suggested both IGHG3 and AHNAK2 need further 
investigation to understand their association to pancreatic cancer, as their increased protein 
expression could be a prospective marker for PC.  
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Cell Lines 
The current project was designed to evaluate levels of protein expression of these 
potential biomarkers in a variety of tumor cell lines compared to a control cell line.  We have 
used immortal human pancreatic duct epithelial (HPDE) cells as a control pancreatic cell line.  
HDPE cells demonstrate a similar gene expression pattern to normal, non-tumorigenic pancreatic 
cells as compared to a cancerous cell line (Ouyang et al., 2000). This research proposes to use 
the immortal human pancreatic duct epithelial (HPDE) cells as a control for our future studies on 
pancreatic cancer.   
Summary  
Pancreatic cancer will continue to be a deadly diagnosis if we are unable to diagnose the 
disease in its early stages. The current biomarkers and screening tools have not been successful 
in detecting the tumors early enough for successful resection and recovery. Chemotherapy and 
radiotherapy have also not guaranteed success. The necessity for new biomarkers or target genes 
is ongoing. Previous studies have recognized CTHCR1, EPPK1, IGHG3, and AHNAK2 as 
potential new biomarkers; these genes have been found to be expressed at higher levels in 
pancreatic cancers.  However, as there is still limited literature and knowledge, more 
experimentation is needed. The goal of this thesis research project is to specifically quantify the 
protein levels of the suggested genes to determine if the proteins are expressed at higher levels in 
pancreatic cancer cell lines compared to normal pancreatic cells.  This work can then add to the 
current literature for finding new potential biomarkers for pancreatic cancer to improve early 
detection of this lethal disease. 
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Materials & Methods 
Cell culture 
          A panel of six pancreatic tumor cell lines of human origin were obtained from the 
American Type Culture Collection (ATCC). The cell lines included PANC-1, BxPc-3, AsPC-1, 
Capan-2, HPAF-II, and CFPA-1. Human Pancreatic Duct Epithelial cells, HPDE-6, is a non-
tumorigenic cell line and was used as a control cell line. All cells were grown to confluence at 
37°C in a humidified 5% CO2 incubator and were passaged every 2-4 days depending on cell 
growth. Cell culture medium varied for all cell lines.  HPDE-6 cells were grown in Keratinocyte 
SFM supplemented with EGF and bovine pituitary extract and with 1% antibiotic-antimycotic. 
ATCC-formulated RPMI-1640 Medium was used for AsPC-1 and BxPC-3.  ATCC-formulated 
Dulbecco’s Modified Eagle’s Medium was used for PANC-1. ATCC-formulated McCoy’s 5a 
Medium was used for Capan-2. ATCC-formulated Eagle’s Minimum Essential Medium was 
used for HPAF-II. ATCC-formulated Iscove’s Modified Dulbecco’s Medium was used for 
CFPAC-1. ATCC-formulated Leibovitz’s L-15 Medium was used for SW 1990, and SW 1990 
was the only cell line grown in a free gas exchange with atmospheric air incubator due to the L-
15 medium formulation. All cell line mediums had fetal bovine serum (FBS) to a final 
concentration of 10% and 1% penicillin/streptomycin added.  
Protein isolation and quantification 
          Total protein was harvested from a 100 mm tissue culture dish containing cells that were 
80-100% confluent. Cell lysates were prepared according to the protocol provided from Santa 
Cruz Biotechnology utilizing RIPA buffer (1X Lysis Buffer: 1X TBS, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 0.004% sodium azide). The RIPA buffer was supplemented 
11 
 
with PMSF (2 mM), sodium orthovanadate (1 mM), and protease inhibitor cocktail.  To 
solubilize cellular proteins, 0.5 mL of complete RIPA buffer /100 mm dish was added with the 
plates on ice. The plates were gently rocked while on ice for 15 minutes, and then a cell scraper 
was used to remove the adherent cells which the resulting lysate was transferred into a micro-
centrifuge tube. The lysate was passed through a 25-gauge needle to shear the DNA, and then the 
tube of lysate was incubated on ice for 30 minutes. After incubation, the cell lysate was 
centrifuged at 10,000 rpm for 10 minutes at 4̊ C. The supernatant fluid, or whole cell lysate, was 
then transferred to a new micro-centrifuge tube, and the pellet is discarded. The cell lysate was 
subsequently quantified by the modified colorimetric Lowry assay (Bio-Rad) or stored at -80C 
and quantified at a later date.  
 A modified Lowry Assay was used to quantify the proteins. Specific amino acids of a 
protein interact with a dye producing a blue color which can be measured at 750nm. Absorbance 
is positively correlated to the amount of protein present. To create a standard curve, known 
dilutions of bovine serum albumin (BSA) from 0 to 2mg/ml were placed into a 96-well plate. 
Five replicates of each standard concentration (0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0mg/ml) were 
added to the plate. Additionally, a dilution of 1:4 or 1:5 of each cell lysate in RIPA buffer was 
also included in the analysis. Five replicates of 5ul of each sample were added to the 96-well 
plate. Next, reagents A and S (Bio-Rad) were combined and 25ul were added to each well. 200ul 
of reagent B (Bio-Rad) was added into each well.  The plate was then incubated at room 
temperature for 15 minutes. During this time, any bubbles present were removed to prevent 
inaccuracies when the absorbance was read.  After 15 minutes, absorbance of the solutions in the 
96 well-plate was read at the wavelength of 750 nm in a spectrophotometer.  A linear regression 
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line was generated using the SoftMax Pro 4.3.1 LS program. The correlation coefficient (R2) had 
to be above 0.97 in order for the data to be used for further analysis.  
Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis 
After protein isolation and quantification, protein extracts from each cell line were 
separated on a sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE). CTHCR1 with a 
molecular weight of 25 kDa migrates farther through the gel than Epiplakin-1 which has 
molecular weight of 552 kDa. This extremely large protein takes longer to pass through the gel.  
To separate CTHCR1 protein from the cell lysate, 22 micrograms of protein were added to a 
12% gel. Before loading the samples containing protein and 6X loading buffer, the protein 
samples were denatured with heat for 5 minutes. The gel was run at room temperature for 55 
minutes at 120 V in 1X Tris-glycine running buffer (25mM Tris base, 190mM glycine, 0.1% 
SDS with pH around 8.3). To separate EPPK1 protein from the cell lysate, a 4-20% gradient 
acrylamide gel was loaded with 30 micrograms of whole cell lysate (protein).The gel was run at 
200V for two hours in 1X Tris-glycine running buffer  at 4̊ C.   After gel electrophoresis, the 
proteins were transferred to a PVDF membrane using the iBlot 2 Dry Blotting System. The 
membrane was then subjected to immunoblot analysis, described in the following section, or 
stored at 4 degrees Celsius until analysis at a later time.  
Immunoblot analysis 
  Immunoblot analysis was used to identify the target protein on the PDVF membrane. 
Blocking the membrane prevents non-specific binding of antibodies; the primary antibody binds 
to the specific target protein, while the specific secondary antibody binds to the primary 
antibody. The secondary antibody has an enzyme conjugated to it which allows a detectable 
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signal to be produced upon addition of substrate.  In these experiments, the protein containing 
PVDF membrane was incubated at room temperature in 5% milk in TBS blocking solution (5 
grams per 100 ml of Tris Buffer Saline) for one hour with rocking followed by a TBS (Tris 
Buffer Saline) wash for ten minutes, TBS-T (Tris Buffer Saline Tween20) wash for ten minutes, 
and then TBS wash again for ten minutes. Next, the PVDF membrane was incubated with a 
primary antibody targeted against the specific proteins (either anti-CTHCR1 or anti-EPPK1) at 
various dilutions (1:50 – 1:300) in TBS-T or TBS buffer overnight at 4 degrees Celsius.  
Following overnight incubation with rocking, blots were washed with TBS and TBS-T as stated 
above, and subsequently probed with a secondary antibody in TBS-T or TBS buffer for one to 
three hours gently rocking at room temperature. Following exposure to the secondary antibody, 
the unbound secondary antibody was removed and a wash series of TBS and TBS-T as stated 
previously was performed to the membranes.  
Visualization of the Protein Bands 
After the final wash, proteins were visualized using a chemiluminescence kit (Western 
Lightning). Western Lighting is a non-radioactive, enzymatic reaction light-emitting system 
designed to detect proteins immobilized on a membrane using an imaging system. Membranes 
were incubated with gentle agitation for 30 to 40 seconds in equal parts of the Enhanced Luminol 
Reagent and the Oxidizing Reagent. The membranes were then removed from the solution and 
excess reagent was drained off. The STORM 860 phosphoimager was used immediately after to 
scan the membranes. The blue fluorescence channel was used with normal sensitivity, pixel size 
of 200 microns, and a PMT voltage of 800nm. After the membranes were scanned, they were 
washed as stated previously in TBS and TBS-T, and then were ready to be stripped. 
Visualization of bands used the Image Quant 5.2 program. Using the Image Quant 5.2 program, 
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each specific protein band was individually selected and then the pixel volume was computed. 
These volumes were entered into a spread sheet for analysis. 
Actin Normalization  
In order to normalize the concentrations of the targeted proteins from each of the blots, 
each blot was stripped of its previous antibodies and reprobed with an antibody to actin, a protein 
found in similar concentrations in most cells.  The blots were stripped in stripping buffer (62.5 
mM Tris-HCL H 6.8, 2% SDS, 100 mM 2-mercaptoethanol). Blots were incubated for 2 hours 
with gentle agitation at 50̊ C. Then the membranes were washed in TBS-T for 5 minutes, 6 times. 
The chemiluminescence kit (Western Lightning) was then used to make sure all bands had 
disappeared. Then membranes were washed again in TBS-T as explained previously. At this 
point, the blots were ready for reuse and incubated for 1 hour at room temperature with gentle 
rocking in 5% milk TBS-T blocking solution followed by TBS wash for ten minutes, TBS-T 
wash for ten minutes, and then TBS wash again for ten minutes. Blots were re-probed with anti-
actin primary antibody (Santa Cruz Biotechnology, 1:200) followed by a wash cycle and then a 
complementary secondary antibody (Santa Cruz Biotechnology, 1:2,000), then visualization and 
quantification as previously described.  
Normalization is commonly used when measuring gene expression relative to a reference 
sample such as actin. Actin is a “house-keeping gene” found in all cells and is required for basic 
cellular functions. To evaluate fold change determination, the intensity values from CTHCR1 
and corresponding actin intensity values were used. However, ratios of the intensity of the 
protein CTHCR1 in the tumorigenic cell line compared to the control HDPE-6 intensity values 
were first calculated. As there were two HPDE-6 intensity values from each gel, the values were 
averaged and used to calculate the ratios.  This was done for the CTHCR1 protein and for the 
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actin protein.  In order to normalize the values of the CTHCR1 to the level of actin, the 
calculated ratio (tumorigenic cell line/HDPE-6) of the CTHCR1 protein was divided by the actin 
ratio (tumorigenic cell line/HDPE-6) to determine the normalized fold change. If this ratio was 
greater than one, there was overexpression of the protein in tumorigenic cell lines compared to 
control, if the ratio was below one, tumorigenic cell lines showed decreased expression of 
CTHCR1 compared to control. 
Statistical Analysis 
Quantification of bands calculated the expression of the target protein in tumorigenic cell 
lines compared to control HDPE cells. In the analysis, three different samples from each cell line 
were used in the analysis. As described above, the band intensity values were normalized with an 
actin control and compared to the control cell line, HDPE.  One way ANOVA with a two sided 
Dunnett’s t-Test for post-hoc analysis was performed using the normalized fold values to 
determine statistical significance where p<0.05 was considered statistically significant. 
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Results 
Currently, pancreatic cancer has a poor prognosis which could be explained by the 
asymptomatic progression, late detection, and lack of effective treatments. This research was 
based on an effort to provide new, potential biomarkers to help with earlier detection of 
pancreatic cancer. Protein extracts from several human pancreatic cell lines were evaluated for 
the expression of several potential protein biomarkers and compared to levels found in non-
tumorigenic pancreatic cell line that served as control.  Western blot analysis was used in this 
comparison.  We were able to test two potential biomarkers:  CTHCR1 and EPPK1. 
CTHCR1 
CTHCR1, collagen triple helix repeat containing-1, is a secreted protein approximately 
30 kilo Daltons (kDa), and expressed at high levels during vascular remodeling and tissue repair 
(Beachy et al., 2004). It was suggested as a significantly upregulated protein in work by 
Goonesekere et al. (2014). This thesis work through western blot analysis found levels of 
CTHCR1 to be significantly increased in one of the seven human pancreatic cancer cells that 
were tested (Figure 1). The other six cell lines tested did not have any significant change in 
levels of CTHCR1.  Figure 1 is a representative gel for CTHCR1.  The gel order is shown with 
the molecular weight marker in the first lane, two unique samples of control HPDE-6, and one 
sample from each of the 7 tumorigenic cell lines.  Three separate gels with this order were run 
and analyzed. The protein samples were each distinct on each gel, that is, each tumorigenic 
sample was from 3 different cell passages of each cell line. There are non-specific bands 
visualized on the blot as well.  In the blot, SW 1990, in the far right lane, has the greatest amount 
of CTHCR1 as quantified by measuring the band intensity using Image Quant software.  
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Figure 1. Western blot analysis shows protein extracted from HPDE-6 cells (control) and one 
individual, distinct sample from each of the seven pancreatic tumor cell lines. A band at the 
expected region for CTHCR1, 26 kDa, can be seen in western blots. A molecular weight marker 
is present on the left. This is a representative blot of the 3 replicates used in the analysis. 
 
Figure 2 shows the previous blot after stripping it of anti-CTHCR1 antibodies and re-
probing with anti-Actin antibody. Actin is a housekeeping gene involved in cell structure and 
motility, and found in almost all cell types; it was used to determine a normalized fold change for 
the CTHCR1 in tumorigenic cell lines compared to the HDPE-6 control cells.  To make sure that 
intensity values were different based on altered expression and not based on unequal amounts of 
total protein loaded in each well, comparisons were made with actin since this protein is not 
changed in the tumorigenic cell lines.  The band intensity was used to normalize the results of 
CTHCR1. Actin appeared in all the cell types and produced very consistent bands. 
 
 
Figure 2. This is the corresponding blot from figure 1 after stripping CTHCR1 antibodies and 
re-probing with anti-actin. Western blot analysis shows protein extracted from HPDE-6 cells 
(control) and one individual, distinct sample from each of the 7 pancreatic tumor cell lines 
express the protein, actin, which is expected. A molecular weight marker is on the left.   
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Table 1 in Excel spreadsheet outlines the calculation process of determining the various 
values of each blot.  The volumes from each of the CTHCR1 bands and Actin bands were 
determined by measuring the band intensity by Image Quant software.  The two control HPDE-6 
volumes were averaged from each study; the ratio of “Sample Vol. / Control Vol.” was 
calculated between control and the samples from the tumorigenic cell lines by dividing the tumor 
cell line volume by the average HDPE-6 volume. This was also performed for the actin protein. 
The “Sample Vol. /Actin vol” column in the table shows the sample volume divided by the 
corresponding actin volume ratio.  “Normalized fold change” of the table shows the normalized 
fold change by dividing the ratio of the sample volume/ actin volume ratio by same ratio of the 
control HPDE-6 sample . This process was repeated for the three replicate blots.  
 
Table 1. Analysis of CTHCR1 band intensities to calculate fold change of protein in tumorigenic 
pancreatic cell lines compared to control cells. 
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Table 2. CTHCR1 statistical analysis using One-way ANOVA. 
 
Table 2 shows the calculated normalized ratios for all of the samples. The table also 
shows the average of each cell line’s normalized ratios and the standard error of the mean of 
each sample. For cell line HPAF-II, there are only two samples as there was an error in the 
loading process and a third replicate was not available. Table 2 shows that pancreatic cell lines 
AsPC1 and BxPC3 have decreased expression of the protein CTHCR1 as compared to the 
control cell line HPDE-6. The other five pancreatic tumor cell lines (Capan-2, CFPAC-1, HPAF-
Cell line
Normalized fold 
change ratios
Average of 
Normalized Ratios
Standard Error of 
the Mean
HPDE6 1 1 0
HPDE6 1
HPDE6 1
HPDE6 1
HPDE6 1
HPDE6 1
AsPC1 1.026886443 0.909089779 0.201558259
AsPC1 0.516319976
AsPC1 1.1840629
BxPC3 0.868266588 0.635674284 0.181087922
BxPC3 0.759803007
BxPC3 0.278953255
CAPAN 0.868266588 1.05537445 0.198856934
CAPAN 1.452861313
CAPAN 0.84499545
CFPAC 0.635930922 1.32077718 0.342497379
CFPAC 1.650848583
CFPAC 1.675552035
HPAF-II 1.423598247 1.206709816 0.216888432
HPAF-II 0.989821384
Panc-1 0.90487261 1.091981275 0.14079838
Panc-1 1.367786293
Panc-1 1.003284923
SW-1990 2.401623713 1.817707951 0.420680245
SW-1990 2.050342668
SW-1990 1.001157473
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II, PANC-1, and SW 1990) show increased expression compared to HPDE-6 cell lines.  SW 
1990 appears to have the greatest overexpression of CTHCR1, almost a two-fold increase.  Table 
3 below shows the results of the ANOVA multiple comparison Dunnett’s t-test.  Only one cell 
line showing statistical significance was SW 1990 with p value of 0.044, showing it was 
significantly altered compared to HPDE-6. The other samples were not statistically significant 
with values above 0.05. Figure 3 below shows the results from Table 2 and Table 3 in graphical 
format. 
 
 
Table 3. ANOVA Dunnett’s t-test results for CTHCR1. Compares protein expression of the panel 
of human pancreatic tumor cell lines to the control cell line. SW 1990 shows statistical 
significance with a value below 0.05. 
Dunnett t (2-sided)a
Variable Control
Mean 
Difference Std. Error Significance
AsPC1 HPDE6 -.09091 0.271644176 1.000
BxPC3 HPDE6 -.36433 0.271644176 0.698
Capan-2 HPDE6 .05537 0.271644176 1.000
CFPAC-1 HPDE6 .32078 0.271644176 0.800
HPAF-II HPDE6 .20671 0.313667677 0.986
PANC-1 HPDE6 .09198 0.271644176 1.000
SW 1990 HPDE6 .81771* 0.271644176 0.044*
*. The mean difference is significant at the 0.05 level.  *. Significant when below 0.05
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
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Figure 3. CTHCR1 expression levels in a panel of human pancreatic tumor cell lines. Each cell 
line was normalized with actin and formulated a normalized ratio of sample volume over control 
volume. Error bars represent the standard error of the mean for each cell line. HDPE-6 is the 
control cell line.  Ratios above 1.0 show increased expression compared to control and those 
below 1.0 show decreased levels of this protein. SW 1990, indicated with an asterisk, is the only 
statistically significant cell line with increased CTHCR1 expression. 
 
In Figure 3, the horizontal axis is the specific cell line and the vertical axis is each cell 
lines’ average of normalized fold change ratios (From Table 2). Error bars represent the standard 
error of the mean of each cell line. The HPDE-6 is the control cell line with a baseline ratio of 1. 
AsPC-1 and BxPC-3 show decreased expression of CTHCR1 while the other cell lines have 
increased expression.  However, these alterations in expression did not prove statistically 
significant except for SW 1990. SW 1990 has an almost two- fold increase of expression of 
CTHCR1 over the control HPDE-6 (Figure 3). 
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EPPK1 
EPPK1 was another protein found to be significantly upregulated in the previous analysis 
performed by Goonesekere et al. (2014). It is a larger in molecular weight at 552 kDa and is 
associated with the cytoskeleton proteins. Western blot analysis on the protein EPPK1 was 
attempted and it proved difficult to obtain results. With EPPK1’s molecular weight at 552 kDa, 
results from gel after transfer showed that the protein did not fully transfer from the gel to the 
membrane. As shown in Figure 4 there was a significant amount of protein left in the wells of the 
gel where EPPK1 and higher molecular weight proteins would be located. The darker coloration 
of purple indicates more protein.  
 
 
 
Figure 4. A gel for EPPK1 after SDS-Page and transfer of proteins to membrane stained in 
Coomassie Blue stain and dried showing a significant amount of protein left over in the wells of 
the gel. 
 
 
Incomplete transfer leads to less protein on the membrane. When the membranes were 
probed with anti-EPPK1 antibodies, no bands were visualized as shown in Figure 5.  In one 
instance, there was an experiment when a faint band could be seen near the top of the membrane 
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as seen in Figure 6 that was suspected to be EPPK1; however, the band located in this region of 
the membrane was never visualized more than once even though several modifications of 
methods were attempted such as increasing the transfer time, increasing the intensity of voltage, 
varying the dilutions of primary and secondary antibodies and the medium of 
diluent.  Additionally, the amount of protein loaded onto the gel was also increased from 22ug to 
50ug; however, EPPK1 could not be visualized more than one time. 
 
 
 
 
 
 
Figure 5. Example of a Western blot with no visible bands in the EPPK1 region probed with 
anti-EPPK1 antibody. A molecular weight protein is seen on the far left and in the 6th lane. 
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Figure 6. Western blot analysis shows HPDE-6 (on left) and BxPC-3 (on right) cell lines showed 
protein expression of EPPK1.  Molecular weight marker is on the left. The bands were detected 
at the expected region for Epiplakin-1, 552 kDa. 
 
 
 
IGHG3 and AHNAK2 
Due to restricted time and focus on completing CTHCR1 and EPPK1 analysis, evaluation 
of IGHG3 and AHNAK2 protein levels was not performed at this time. CTHCR1 and EPPK1 
required an extensive amount of time to optimize the western blot methods. 
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Discussion 
This thesis project was based on a previous meta-analysis study to suggest several 
cellular genes including, CTHCR1, EPPK1, AHNAK2, and IGHG3, as potential biomarkers for 
pancreatic cancer (Goonesekere et al., 2014). Our goal was to determine if protein expression of 
these genes was altered in a variety of human pancreatic tumor cell lines. Significant changes in 
protein expression in tumor cell lines compared to control could disclose a new potential 
biomarker to help in earlier diagnosis of pancreatic cancer leading to better treatment options. 
Cell culture, protein isolation and quantification followed by Western blot analysis was 
performed. The results showed that there was a significant increase, nearly two-fold, in 
expression of CTHCR1 in the tumorigenic cell line SW 1990 (Figure 3). The human pancreatic 
tumorigenic cell line, SW 1990, was obtained from a 56 year old male who had adenocarcinoma 
of the pancreas derived from the spleen metastatic site. The cell line obtained from the American 
Tissue Cell Collection is epithelial and adherent in nature and did not require 5% CO2 for 
growth, unlike the other cell lines used in this study. There was also a trend of increased 
expression in CTHCR1 in four other pancreatic tumor cell lines (Table 2), there was no 
statistically significant increase in protein expression. In contrast, two pancreatic tumor cell lines 
that had decreased expression of the protein CTHCR-1, however, these levels were also not 
statistically significant. 
 CTHCR1, also known as collagen triple helix containing 1, has been associated with 
multiple other cancers other than pancreatic cancer. CTHCR1 is a secreted protein around 30 
kDa and its function is related to tissue repair (Goonesekere et al., 2014). A prior study looked at 
CTHCR1’s presence and role in melanoma and other human solid cancer cells. The potential 
biomarker was found to be expressed at the mRNA and protein levels in melanoma cancer cells 
26 
 
(Tang et al., 2006). Although the study did not find a significant function of CTHCR1, CTHCR1 
was found at much higher levels in invasive melanoma compared to a noninvasive type which 
suggests CTHCR1 may play a role in migration and metastasis. The same study by Tang et al. 
found that the majority of 19 human solid cancers had increased expression of CTHCR1, such as 
cancers of the pancreas, rectum, colon, small intestine, cervix, thyroid gland, lung, ovary, and 
breast; however, testis, prostate, and trachea tumors were the exception and showed no 
significant increase (Tang et al., 2006). These results add to our finding that CTHCR1 was 
upregulated in the pancreatic tumor cell line compared to control. The meta-analysis study 
showed that CTHCR1 was greater than a 1,000 fold increase in protein expression (Goonesekere 
et al., 2014).  While in our hands, there was only a two-fold significance of CTHCR1 in a 
cancerous cell line to control there was still an increase and thus suggests that CTHCR1 can still 
be a potential biomarker with future research.  
Challenges faced in the research 
Western blot analysis can be a challenging technique. The CTHCR1 and EPPK1 studies 
took much longer than expected. Optimizing the western blot protocol to visual bands was a long 
process and took many different trials and variations. There were 40 total western blots run over 
the span of doing research with several blots divided off into small segments meaning even more 
trials.  For CTHCR1, the amount of isolated total protein loaded onto the gel ranged from 22 to 
35 micrograms (ug) of protein with the attempt to get a stronger, visible signal. For EPPK1, total 
isolated protein ranged from 22 ug to 50 ug. Transfer time of the protein was also adjusted many 
times. A wet transfer method of transfer was first used, then the iBlot system was used; this 
system was much more efficient not only in the time of transfer, but the amount of protein that 
was transferred. The temperature conditions, dilution solution such as TBS, TBS-T, or 5% milk 
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in TBS, or 5% milk in TBS-T, and length of time of the primary and secondary antibody 
incubations were also modified. CTHCR1 ranged ratios of primary from 1:100 to 1:300 and 
secondary from 1:2,000 to 1:15,000. EPPK ranged ratios of primary from 1:100 to 1:500 and 
secondary from 1:1,500 to 1:10,000. Western blot analysis is time-consuming considering that 
each blot takes two to three days and then if stripping and reprobing the blot, another two days 
must be added. Western blot analysis takes time, persistence, and longevity to optimize the 
protocol.    
Future Suggested Work  
Several areas of future work can be expanded from this thesis. More trials of western 
blots looking at CTHCR1 could be obtained for a stronger statistical analysis. In this current 
study, there were only three replicates. Other than SW 1990 showing significant expression the 
protein CTHCR1, tumorigenic cell line, BxPC3, appeared to have only half the expression of the 
control cell line. This was not found significant at this time; however, with more trials, it may be 
found significant. Another way to enhance this study would be to remove the background bands. 
Several of the blots of CTHCR1 show excess signal of non-specific bands even after numerous 
runs. The multiple bands can come from excess of primary or secondary antibodies; multiple 
optimization experiments to adjust concentrations would need to occur. In future studies, more 
time could be allowed for this. More optimization experiments to find the lowest concentration 
of isolated protein needed to detect a band would also be constructive.  
EPPK1 was very challenging to visualize. EPPK1 was one of the higher molecular 
weight proteins at 552 kDa along with AHNAK2 at approximately 600 kDa. Incomplete transfer 
of the protein from the gel to the membrane would be an area to focus on in future work. Even 
though 17 western blots were run for EPPK1, there was only one faint band visualized once. 
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Unfortunately, this visualization was never repeated. This is a very small victory, but shows 
there is room for more improvement with more time.  
Due to time restrictions and the difficulties of visualizing CTHCR1 and EPPK1, IGHG3 
and AHNAK2 were not evaluated using western blot analysis at this time. Our lab has frozen 
down samples of the pancreatic tumor cell lines and control cell line and stored the isolated 
protein samples. An antibody used to detect IGHG3 has been purchased and is ready to use. 
IGHG3 has a smaller molecular weight, similar to CTHCR1, and with more time, IGHG3 should 
be easily visualized on western blots.  In contrast, I do expect the AHNAK2 will be difficult to 
transfer similar to EPPK1 due to its high molecular weight of approximately 600 to 630 kDa. 
This research will hopefully be continued in the future. 
Another aspect of future work would be comparing the results of protein expression to 
the results from the RNA expression study performed. As mentioned earlier, this research was 
part of a two-part study with half looking at expression of the target gene at the RNA level 
through qPCR and the other half at the protein level through western blot analysis. Comparing 
these results from both parts of research could add supporting evidence that one of the four genes 
could be a potential biomarker for pancreatic cancer.  
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Conclusions 
Pancreatic cancer is commonly discovered and diagnosed at a later stage when the cancer 
has spread or metastasized beyond surgical resection. Even with traditional therapies, a patient 
with advanced stages of PC has a very poor prognosis and life expectancy. PC is asymptomatic 
in early stages; finding a new, alternative way to detect pancreatic cancer early on is inevitable 
for better treatment options. Therefore, research has been focused on finding new biomarkers 
which are specific indicators of a certain disease. The current project was based on work using 
bioinformatics data by Goonesekere et al. (2014). The investigators suggested CTHCR1, EPPK1, 
AHNAK2, and IGHG3 as potential biomarkers for pancreatic cancer. The goal of this thesis was 
to determine if protein expression of these genes was altered in a variety of human pancreatic 
tumor cell lines through western blot analysis. CTHCR1 results showed a significant increase of 
protein expression in SW 1990, a pancreatic tumor cell line, compared to the HPDE-6 control 
cell line. This suggests that this human tumorigenic cell line had an increased level of CTHCR1 
protein when compared to amounts found in a cell line that appeared to be normal. This data 
adds to the current that evidence that CTHCR1 can act as a prospective pancreatic cancer 
biomarker. There was also increased CTHCR1 protein expression in four other human pancreatic 
tumorigenic cell lines, but they were not found statistically significant. EPPK1 was another 
potential biomarker mentioned significantly upregulated in a previous study (Goonesekere et al., 
2014); however, its large molecular weight was a challenge and caused insufficient transfer of 
proteins. Several adjustments were made, but unfortunately no bands indicating present proteins 
were visualized. More time and research will be needed to look more into EPPK1, AHNAK2, 
and IGHG3, and also in repeating CTHCR1. In conclusion, these new findings about CTHCR1 
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will add to the literature of potential biomarkers for pancreatic cancer which in the future will 
lead to earlier detection and much better prognosis.  
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